A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection.

A booster dose of a formalin-inactivated, cell culture-propagated Rift Valley fever vaccine (TSI-GSD-200) was administered without significant reactogenicity to 60 volunteers 18 months after they received a three dose primary series. Blood was drawn for serological testing prior to boosting and 10, 49, and 180 days thereafter. Neutralizing antibody response was prompt, being maximum on day 10 and considerably higher than the peak titres obtained on day 42 after the initial series.

A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up.

A formalin-inactivated Rift Valley fever vaccine, originally produced in primary monkey kidney cells, has been used to protect laboratory workers. A trial of a modified vaccine, newly formulated in well-characterized diploid fetal rhesus lung cells, was conducted with 114 men aged 19--24 years. Of the 107 subjects who received up to three injections of 0.

A serological survey of Rift Valley fever antibodies in the northern Sinai.

In the aftermath of an extensive Egyptian Rift Valley fever (RVF) epidemic during 1977-78, RVF activity in the adjacent Sinai peninsula has been inferred from the presence of haemagglutination-inhibition (HI) antibodies in sera from indigenous humans and rodents. We attempted to confirm these findings by HI testing of sera from Israeli soldiers serving in the region of the El Arish Wadi system in the Sinai, and from indigenous rodents. Six of 199 human sera (3.